HCAT vs TDOC

For growth investors, Health Catalyst, Inc.

(HCAT) is the stronger pick with 1. 5% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Analysts rate Health Catalyst, Inc. (HCAT) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Teladoc Health, Inc.

(TDOC) delivered a total return of -95. 4%, compared to -97. 0% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: TDOC returned -41. 1% versus HCAT's -95. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Teladoc Health, Inc.

(TDOC) is the lower-risk stock at 1. 91β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 7% more volatile than TDOC relative to the S&P 500. On balance sheet safety, Health Catalyst, Inc. (HCAT) carries a lower debt/equity ratio of 8% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Health Catalyst, Inc.

(HCAT) is pulling ahead at 1. 5% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, HCAT leads at 4. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Teladoc Health, Inc.

(TDOC) is the more profitable company, earning -7. 9% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps -7. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TDOC leads at -10. 4% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for HCAT: 57.

2% to $2. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Teladoc Health, Inc.

(TDOC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TDOC: -41. 1%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.